Evolus, Inc. (EOLS): Price and Financial Metrics
GET POWR RATINGS... FREE!
EOLS POWR Grades
- EOLS scores best on the Value dimension, with a Value rank ahead of 63.56% of US stocks.
- EOLS's strongest trending metric is Quality; it's been moving down over the last 179 days.
- EOLS ranks lowest in Momentum; there it ranks in the 12th percentile.
EOLS Stock Summary
- Of note is the ratio of Evolus Inc's sales and general administrative expense to its total operating expenses; 98.7% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of -45.96%, Evolus Inc's debt growth rate surpasses only 8.58% of about US stocks.
- As for revenue growth, note that EOLS's revenue has grown 76.29% over the past 12 months; that beats the revenue growth of 88.92% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Evolus Inc are KE, AMSF, CURI, TTCF, and AMPG.
- EOLS's SEC filings can be seen here. And to visit Evolus Inc's official web site, go to www.evolus.com.
EOLS Valuation Summary
- EOLS's EV/EBIT ratio is -3.8; this is 112.97% lower than that of the median Healthcare stock.
- Over the past 43 months, EOLS's price/sales ratio has gone NA NA.
- Over the past 43 months, EOLS's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for EOLS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EOLS | 2021-08-31 | 7.6 | 5.5 | -4.4 | -3.8 |
| EOLS | 2021-08-30 | 7.5 | 5.4 | -4.4 | -3.8 |
| EOLS | 2021-08-27 | 7.6 | 5.5 | -4.5 | -3.8 |
| EOLS | 2021-08-26 | 7.7 | 5.5 | -4.5 | -3.8 |
| EOLS | 2021-08-25 | 7.9 | 5.7 | -4.6 | -4.0 |
| EOLS | 2021-08-24 | 7.9 | 5.7 | -4.6 | -4.0 |
EOLS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EOLS has a Quality Grade of C, ranking ahead of 44.26% of graded US stocks.
- EOLS's asset turnover comes in at 0.373 -- ranking 125th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows EOLS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.373 | 0.630 | -3.772 |
| 2021-03-31 | 0.300 | 0.674 | -1.580 |
| 2020-12-31 | 0.271 | 0.676 | -1.214 |
| 2020-09-30 | 0.256 | 0.735 | -0.356 |
| 2020-06-30 | 0.245 | 0.734 | -0.491 |
| 2020-03-31 | 0.216 | 0.731 | -0.603 |
EOLS Price Target
For more insight on analysts targets of EOLS, see our EOLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.14 | Average Broker Recommendation | 1.57 (Moderate Buy) |
EOLS Stock Price Chart Interactive Chart >
EOLS Price/Volume Stats
| Current price | $13.61 | 52-week high | $14.34 |
| Prev. close | $11.87 | 52-week low | $5.06 |
| Day low | $11.84 | Volume | 778,123 |
| Day high | $13.76 | Avg. volume | 507,067 |
| 50-day MA | $11.55 | Dividend yield | N/A |
| 200-day MA | $8.73 | Market Cap | 762.83M |
Evolus, Inc. (EOLS) Company Bio
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California.
Latest EOLS News From Around the Web
Below are the latest news stories about Evolus Inc that investors may wish to consider to help them evaluate EOLS as an investment opportunity.
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should KnowEvolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business UpdateNEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its fourth quarter and year end 2021 financial results and provide a business update on Thursday, March 3, 2022. |
Evolus (EOLS) Investor Presentation - SlideshowNo summary available. |
Evolus'' request to market anti-wrinkle therapy accepted in AustraliaEvolus < |
Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®NEWPORT BEACH, Calif., February 08, 2022--Evolus announces the acceptance of its submission to the Australian Therapeutics Good Administration for regulatory approval of Nuceiva® |
EOLS Price Returns
| 1-mo | 18.14% |
| 3-mo | 47.29% |
| 6-mo | 138.77% |
| 1-year | 25.67% |
| 3-year | -6.20% |
| 5-year | N/A |
| YTD | 109.06% |
| 2021 | 93.75% |
| 2020 | -72.39% |
| 2019 | 2.27% |
| 2018 | N/A |
| 2017 | N/A |
Continue Researching EOLS
Want to see what other sources are saying about Evolus Inc's financials and stock price? Try the links below:Evolus Inc (EOLS) Stock Price | Nasdaq
Evolus Inc (EOLS) Stock Quote, History and News - Yahoo Finance
Evolus Inc (EOLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...